Trial · NCT00577135

Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)

NCT00577135, Phase 3, Completed, Duke University; results first posted 2013-05-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study). Trials, record NCT00577135. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00577135

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)
NCT number: NCT00577135
Status: Completed
Phases: Phase 3
Enrollment: 308 participants, actual
Lead sponsor: Duke University
Conditions: Heart Failure
Interventions: Furosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification, Furosemide-High Intensification
First posted: 2007-12-19
Last updated: 2018-03-06
Results first posted: 2013-05-27

Source ClinicalTrials.gov

Registered outcomes28

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Patient Well Being, as Determined by a Visual Analog Scale	Measured at 72 hours	Global Visual Analog Scale Scale Range 0-7200; higher score is better
Primary	Change in Serum Creatinine	Measured at baseline and 72 hours
Secondary	Change in Weight	baseline and 96 hours
Secondary	Proportion of Patients Free of Congestion	Measured at 72 hours
Secondary	Dyspnea, as Determined by Visual Analog Scales	Measured at 24 hours	Global Visual Analog Scale Scale Range 0-2400; higher score is better
Secondary	Change in Serum Creatinine	baseline and 24 hours
Secondary	Change in Cystatin C	baseline and 72 hours
Secondary	Change in Serum Creatinine	baseline and 48 hours
Secondary	Change in Serum Creatinine	baseline and 96 hours
Secondary	Change in Serum Creatinine	baseline and day 7

1 to 10 of 28Source ClinicalTrials.gov

See all 28 registered outcomes

Outcomes28

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Patient Well Being, as Determined by a Visual Analog Scale	Measured at 72 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	units on a scale	MEAN
PRIMARY	Change in Serum Creatinine	Measured at baseline and 72 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	mg/dL	MEAN
SECONDARY	Change in Weight	baseline and 96 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	lbs	MEAN
SECONDARY	Proportion of Patients Free of Congestion	Measured at 72 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	percentage of participants	NUMBER
SECONDARY	Dyspnea, as Determined by Visual Analog Scales	Measured at 24 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	units on a scale	MEAN
SECONDARY	Change in Serum Creatinine	baseline and 24 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	mg/dL	MEAN
SECONDARY	Change in Cystatin C	baseline and 72 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	mg/L	MEAN
SECONDARY	Change in Serum Creatinine	baseline and 48 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	mg/dL	MEAN
SECONDARY	Change in Serum Creatinine	baseline and 96 hours	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	mg/dL	MEAN
SECONDARY	Change in Serum Creatinine	baseline and day 7	Each analysis performed for this trial was done twice. The first analysis compared Q12hour versus continuous, the second analysis compared low intensification versus high intensification. The study was not testing the combined 4 way as a pre-specified analysis.	mg/dL	MEAN

1 to 10 of 28Source ClinicalTrials.gov

See all 28 outcomes

Results by group112

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Patient Well Being, as Determined by a Visual Analog Scale	Q 12 Hour Bolus	4236	Standard Deviation 1440.4	units on a scale
Patient Well Being, as Determined by a Visual Analog Scale	Continuous Infusion	4372.7	Standard Deviation 1404.4	units on a scale
Patient Well Being, as Determined by a Visual Analog Scale	Low Intensification	4170.8	Standard Deviation 1436.3	units on a scale
Patient Well Being, as Determined by a Visual Analog Scale	High Intensification	4429.6	Standard Deviation 1401.4	units on a scale
Change in Serum Creatinine	Q 12 Hour Bolus	0.05	Standard Deviation 0.30	mg/dL
Change in Serum Creatinine	Continuous Infusion	0.07	Standard Deviation 0.30	mg/dL
Change in Serum Creatinine	Low Intensification	0.04	Standard Deviation 0.29	mg/dL
Change in Serum Creatinine	High Intensification	0.08	Standard Deviation 0.31	mg/dL
Change in Weight	Q 12 Hour Bolus	-8.0	Standard Deviation 7.8	lbs
Change in Weight	Continuous Infusion	-9.1	Standard Deviation 10.2	lbs

1 to 10 of 112Source ClinicalTrials.gov

See all 112 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Q12 Hours Bolus & Low Intensification	74
Overall Study	STARTED	Q12 Hours Bolus & High Intensification	82
Overall Study	STARTED	Continuous Infusion & Low Intensification	77
Overall Study	STARTED	Continuous Infusion & High Intensification	75
Overall Study	COMPLETED	Q12 Hours Bolus & Low Intensification	74
Overall Study	COMPLETED	Q12 Hours Bolus & High Intensification	82
Overall Study	COMPLETED	Continuous Infusion & Low Intensification	77
Overall Study	COMPLETED	Continuous Infusion & High Intensification	75
Overall Study	NOT COMPLETED	Q12 Hours Bolus & Low Intensification	0
Overall Study	NOT COMPLETED	Q12 Hours Bolus & High Intensification	0

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events92

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
serious	Cardiac Failure	Cardiac disorders	Q 12 Hour Bolus	17	156
serious	Cardiac Failure	Cardiac disorders	Continuous Infusion	18	152
serious	Cardiac Failure	Cardiac disorders	Low Intensification	20	151
serious	Cardiac Failure	Cardiac disorders	High Intensification	15	157
serious	Cardiac Failure Acute	Cardiac disorders	Q 12 Hour Bolus	13	156
serious	Cardiac Failure Acute	Cardiac disorders	Continuous Infusion	6	152
serious	Cardiac Failure Acute	Cardiac disorders	Low Intensification	9	151
serious	Cardiac Failure Acute	Cardiac disorders	High Intensification	10	157
serious	Ventricular Tachycardia	Cardiac disorders	Q 12 Hour Bolus	7	156
serious	Ventricular Tachycardia	Cardiac disorders	Continuous Infusion	4	152

1 to 10 of 92Source ClinicalTrials.gov

See all 92 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Q 12 Hour Bolus
Total, all-cause mortality	Continuous Infusion
Total, all-cause mortality	Low Intensification
Total, all-cause mortality	High Intensification
Total, other adverse events	Q 12 Hour Bolus	0	0
Total, other adverse events	Continuous Infusion	0	0
Total, other adverse events	Low Intensification	0	0
Total, other adverse events	High Intensification	0	0
Total, serious adverse events	Q 12 Hour Bolus	69	156
Total, serious adverse events	Continuous Infusion	67	152

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers8

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
21366472	RESULT	PubMed
23194486	DERIVED	PubMed
23250981	DERIVED	PubMed
25543972	DERIVED	PubMed
26041600	DERIVED	PubMed
26927285	DERIVED	PubMed
27514750	DERIVED	PubMed
38775253	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U01HL084904	Heart Failure Clinical Research Network - DCC	LEE, KERRY L	DUKE UNIVERSITY	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2006 to 2011

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00577135

GET https://conductscience.org/api/trials/v1/NCT00577135/registered?page=2

API reference For AI assistants